4 completed, 3 recruiting, 1 withdrawn. 8 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 4, Recruiting 3, Withdrawn 1 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow Rigel Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation Olutasidenib Investigational Agent Administration - Acute Myeloid Leukemia | Phase 1 | Withdrawn | Virginia Commonwealth University | 2026-02-02 | 2026-10-29 | |
| Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD Fostamatinib, Ruxolitinib - Chronic Graft Versus Host Disease | Phase 1 | Recruiting | Stefanie Sarantopoulos, MD, PhD. | 30 | 2025-10-29 | 2026-01-22 |
| Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel) - Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Recruiting | University of California, San Diego | 36 | 2024-12-05 | 2026-04-07 |
| Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) R906289 Monosodium (R289 Na) - Low Risk Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | Rigel Pharmaceuticals | 86 | 2022-09-12 | 2026-11-06 |
| Inflammatory Signal Inhibitors for COVID-19 (MATIS) Ruxolitinib, Fostamatinib, Standard of care - Coronavirus, Covid19 | Phase 1 / Phase 2 | Completed | Imperial College London | 185 | 2020-10-02 | 2025-11-18 |
| Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer Fostamatinib 100 mg bid and Paclitaxel, Fostamatinib 150 mg bid and Paclitaxel, Fostamatinib 200 mg bid and Paclitaxel - Ovarian Cancer | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 35 | 2018-04-03 | 2024-10-24 |
| A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, R348 Ophthalmic Solution, 1.0% - Keratoconjunctivitis Sicca | Phase 1 | Completed | Rigel Pharmaceuticals | 36 | 2012-11-01 | 2014-08-04 |
| Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma fostamatinib - Lymphoma | Phase 1 / Phase 2 | Completed | Rigel Pharmaceuticals | 81 | 2007-04-01 | 2016-09-19 |
Bronchiolitis Obliterans Syndrome (1) · COVID-19 (1) · Coronavirus Infections (1) · Keratoconjunctivitis Sicca (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Myelodysplastic Syndromes (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Pneumonia (1)
fostamatinib (5) · ruxolitinib (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · BID protein, human (1) · Drug Therapy (1) · Gemcitabine (1) · Paclitaxel (1) · Standard of Care (1)
United States (6) · United Kingdom (1)
Andrew Lowy, MD (1) · Chenyu Lin, MD (1) · Gail Torkildsen, MD (1) · Jeffrey Skolnik, M.D. (1) · Keri Maher, DO (1) · Nichola Cooper (1) · Stephanie Gaillard, MD (1)